BS01 gene therapy for dry age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial tests a new gene therapy, BS01, given as an eye injection. It is for people with advanced dry age-related macular degeneration (AMD) that has caused geographic atrophy—damage to the central part of the retina. The study aims to see if the treatment is safe and can help slow vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 85 years old.
- You have geographic atrophy (a type of advanced dry AMD) that affects the center of your vision.
- The damaged area in your eye must be a certain size—between about 2 and 7 times the size of a standard disc in your retina.
- Your vision in the study eye is between 20/50 and 20/400 (meaning you can read the large letter on an eye chart but not the smaller ones).
- You have not had any previous gene therapy or radiation around the eye.
- You have not had eye surgery in the last 3 months, and you do not have any eye infections or certain other eye conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental gene therapy, OCU410, for people with geographic atrophy, an advanced form of dry AMD that causes blind spots in the center of vision. The study aims to see if this treatment can slow down the progression of the disease and help preserve remaining vision.
This trial is testing a new eye implant (TO-O-1007) to see if it's safe and helps slow vision loss from geographic atrophy, a late stage of dry age-related macular degeneration (AMD). The implant is placed inside the eye and releases medicine over time.
This study tests a new gene therapy that may slow or stop the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes vision loss. The treatment is given as an injection into the eye and aims to preserve remaining vision.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This trial tests an investigational eye injection (RO7965032) for people with geographic atrophy, a form of dry age-related macular degeneration that causes progressive vision loss. The goal is to see if the treatment can slow further vision loss and preserve sight.
This trial tests a gene therapy (KH658) as a one-time treatment for wet macular degeneration. It's for people whose condition has been stabilized with anti-VEGF injections, and aims to see if it is safe and can reduce the need for frequent eye injections.
Hear when a new Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.